Peptonic Medical AB (publ) (“Peptonic” eller “Bolaget”) meddelar idag att man beslutat att utnyttja rätten att konvertera det lån om 7,5 Mkr som Bolaget upptog i november 2020 från Vidarstiftelsen.
Read More
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces today that it has decided to exercise the right to convert the loan of SEK 7.5 million that the Company raised
Read More
Stockholm, 14 maj 2020 – Peptonic Medical AB (publ) (’Peptonic’ eller ’Bolaget’) meddelar i dag att Bolagets kvartalsrapport kommer att publiceras senare under dagen.
Read More
Peptonic Medical AB (publ) årsredovisning för verksamhetsåret 2019 finns nu tillgänglig på sidan Financial information. Er tryckt kopia av årsredovisningen kan beställas via e-post info@peptonicmedical.se eller via telefon 0768 550 200. Johan Inborr,
Read More
www.spotlightstockmarket.com, kortnamn: PMED 2019 kvartal 3 (jul-sep) Omsättning produkter 1 557 (120) KSEK Bruttovinst 692 (95) KSEK, 45% (79%) Rörelseresultat -4 127 (-3 420) KSEK Resultat per aktie -0,03 (-0,04)
Read More
www.aktietorget.se ticker: PMED 2019 third quarter (Jul-Sep) Net sales of products KSEK 1,557 (120) Gross profit KSEK 692 (95), Gross margin 45% (79%) Operating loss KSEK -4,127 (-3,420) Loss per
Read More
2019 kvartal 2 (apr-jun) Omsättning produkter 1 011 (0) KSEK Bruttovinst 768 (0) KSEK, 76% (0%) Rörelseresultat -5 102 (-3,563) KSEK Resultat per aktie -0,06 (-0,04) SEK 2019 första halvåret
Read More
2019 first quarter (Apr-Jun) Net sales of products KSEK 1,011 (0) Gross profit KSEK 768 (0), Gross margin 76% (0%) Operating loss KSEK -5,102 (-3,563) Loss per share SEK -0.06
Read More
Basscenariot visar på en riktkurs om 1,40 kr, vilket är avsevärt högre än teckningskursen på 0,83 kr i den pågående företrädesemissionen. Läs hela artikeln på aktiespararna.se »Ladda ner analysen (PDF)
Read More
PEPTONIC Medical (publ) (”PEPTONIC Medical eller ”Bolaget”) – meddelar att Analysguiden med anledning av den pågående företrädesemissionen har publicerat en ny analys av bolaget. Analysguiden är ett oberoende analysföretag som
Read More
The Board of Directors of Peptonic Medical AB (publ) (Peptonic or Company) today announced the decision to commence the process of obtaining CE-marking for the vaginal gel that was used
Read More
Tisdagen den 11 april arrangerade PEPTONIC medical ett informationsmöte med aktieägarna. På mötet berättade styrelse och ledning om den nyss slutförda fas IIb-studien och om planerna framåt. Här nedan presenteras svar på
Read More
Aktieägarna i Peptonic Medical bjuds härmed in till ett informationsmöte den 11 april kl 17-19. Mötet hålls på Scandic Klara, Slöjdgatan 7, Stockholm. Medverkande från bolagets sida är medlemmar ur
Read More
Peptonic Medical AB (publ) today announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel was investigated for the treatment
Read More
Peptonic Medical AB (publ) (“the Company” or “Peptonic”) – a company developing pharmaceuticals based on oxytocin – today announced that 57 study subjects have been randomised in to its phase
Read More
Peptonic Medical (publ) – ett bolag som utvecklar läkemedel baserade på oxytocin – meddelar idag att sex veckor efter start av studien har 57 patienter startat behandling. Under juni månad
Read More
PEPTONIC medical (publ) (”Peptonic Medical eller ”Bolaget”) – ett bolag som utvecklar läkemedel baserade på oxytocin – meddelar att bolaget kommer att delta på Stora Aktiedagen i Stockholm den 7:e
Read More
PEPTONIC medical (publ) – ett bolag som utvecklar läkemedel baserade på oxytocin – kommer att delta på Småbolagsdagen i Stockholm den 8:e juni. Småbolagsdagen arrangeras av Redeye och Aktiespararna på
Read More
Aktieägarna i PEPTONIC medical AB (publ), org.nr 556776-3064 (”Bolaget”) kallas härmed till årsstämma torsdagen den 9 april 2015 kl. 16.30 i Gällöfsta Konferens lokaler, Biblioteksgatan 29, 114 35 Stockholm. Anmälan
Read More
PEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and appointed A+ Science AB as
Read More
Idag noteras PEPTONIC Medical på AktieTorget och i samband med det har VD, Dan Markusson, intervjuats av Redeye. Titta på intervjun » Aktiens handelsbeteckning är PMED. Aktiens ISIN-kod är SE0005962206.
Read More
Peptonic har genomfört en riktad nyemission samt en spridningsemission under maj respektive juni månad som tillsammans tillför bolaget drygt 22 mkr före emissionskostnader. Efter de två emissionerna har bolaget ca
Read More
PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO) on Aktietorget Stock Exchange (Stockholm)
Read More
PEPTONIC medical today announces that, at the PEPTONIC medical Annual General Meeting on April 8th, Mrs Nadia Whittley was elected as a new member to the Board of Directors. Mrs
Read More
PEPTONIC medical (publ) today announced that the Annual General Meeting (AGM) on April 8th resolved to make the Company to a public company. In conjunction with this resolution, a rights
Read More
PEPTONIC medical today announced that it has recruited Johan Inborr to lead the business development activities of the company on a consultancy basis. Johan is an experienced business development executive
Read More
PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement, the number of shareholders in
Read More
PEPTONIC medical today announced that it has completed the evaluation of different tube models and materials for use as primary packaging of VAGITOCIN® – the company’s oxytocin based gel in
Read More
PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician in accordance with the study
Read More
PEPTONIC medical today announced that it met with the US Food and Drug Administration (FDA) earlier this month in a so called pre-IND meeting. The objectives of the meeting were
Read More
PEPONIC medical has signed an agreement with Destum Partners in USA for support in finding suitable collaboration partners. By using a US based consulting company the process to find collaboration
Read More
PEPTONIC has started a collaboration with Clinartis in USA. Clinartis is a consulting company within the clinical/regulatory area. They support us in the work with planning of a so called
Read More
A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13. The results from the recently concluded clinical study and the design of the planned phase III were
Read More
A new formulation patent for oxytocin was approved by the Swedish patent authorities in February 2013. PEPTONIC has received a patent on the new formulation of Vagitocin. Sweden was the
Read More
PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This constituted the possibilities for PEPTONIC
Read More